Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

NCT02950051 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

926

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Fludarabine
DRUG: Cyclophosphamide
BIOLOGICAL: Rituximab
DRUG: Bendamustine
DRUG: Venetoclax
BIOLOGICAL: Obinutuzumab
DRUG: Ibrutinib

Sponsor

German CLL Study Group

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]